Loading…
Sectoral / Thematic · Nippon India Mutual Fund · AMFI code 102431Nippon India Pharma Fund
Disclosed for 84 months, Sep 2019 to Aug 2026.Published as: NIPPON INDIA PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹5,447 Cr
up ₹209 Cr vs May 2021
- Stocks held
- 24
- up 2 vs May 2021
- Top 10 weight
Nippon India Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In June 2021 it disclosed 24 stocks worth ₹5,447 Cr, up ₹209 Cr from May 2021. Its largest positions were Dr. Reddy's Laboratories Limited (9.6%), Divi's Laboratories Limited (9.3%), Sun Pharmaceutical Industries Limited (9.1%); the ten largest together made up 73.0% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 76.3% of its equity. Cash and debt stood at 0.7%. Compared with May 2021 the fund entered 2 new stocks and exited 0.
Against 226 other Sectoral / Thematic funds
Concentration
95%
Top-10 weight is higher than 95% of peers
Breadth
5%
Holds more stocks than 5% of peers
Cash
9%
Holds more cash than 9% of peers
Holdings in June 2021
Download CSVEvery line the fund disclosed, with the change against May 2021. Click a column to sort; click a company to see every fund that owns it.
| Dr. Reddy's Laboratories Limited | 9.56% | down 0.17 pts | ₹521 Cr | up ₹10.9 Cr | Added |
| Divi's Laboratories Limited | 9.31% | up 0.90 pts | ₹507 Cr | up ₹66.6 Cr | Added |
| Sun Pharmaceutical Industries Limited | 9.05% | down 0.52 pts | ₹493 Cr | down ₹8.1 Cr | Trimmed |
| Cipla Limited | 8.56% | down 0.14 pts | ₹467 Cr | up ₹10.8 Cr | Added |
| Aurobindo Pharma Limited | 7.97% | down 0.60 pts | ₹434 Cr | down ₹14.7 Cr | Trimmed |
| Lupin Limited | 7.17% | down 0.74 pts | ₹391 Cr | down ₹23.9 Cr | Trimmed |
| Gland Pharma Limited | 6.61% | down 0.02 pts | ₹360 Cr | up ₹12.7 Cr | Added |
| Fortis Healthcare Limited | 5.45% | down 0.50 pts | ₹297 Cr | down ₹14.7 Cr | Trimmed |
| Zydus Lifesciences Limited | 4.74% | up 0.02 pts | ₹258 Cr | up ₹10.8 Cr | Added |
| Apollo Hospitals Enterprise Limited | 4.60% | up 1.62 pts | ₹250 Cr | up ₹94.6 Cr | Added |
| Thyrocare Technologies Limited | 4.54% | up 0.71 pts | ₹247 Cr | up ₹46.8 Cr | Added |
| Narayana Hrudayalaya Limited | 3.84% | up 0.49 pts | ₹209 Cr | up ₹33.8 Cr | Added |
| Torrent Pharmaceuticals Limited | 3.20% | up 0.84 pts | ₹174 Cr | up ₹50.8 Cr | Added |
| Abbott India Limited | 2.76% | up 0.02 pts | ₹150 Cr | up ₹7 Cr | Added |
| Indoco Remedies Limited | 2.25% | down 0.15 pts | ₹123 Cr | down ₹3 Cr | Trimmed |
| Jubilant Pharmova Limited | 2.02% | down 0.49 pts | ₹110 Cr | down ₹21.3 Cr | Trimmed |
| Sanofi India Limited | 1.86% | down 0.09 pts | ₹101 Cr | down ₹64 L | Trimmed |
| Orchid Pharma Limited | 1.68% | up 1.68 pts | ₹91.4 Cr | up ₹91.4 Cr | New |
| Krishna Institute Of Medical Sciences Limited | 1.52% | up 1.52 pts | ₹82.8 Cr | up ₹82.8 Cr | New |
| Jubilant Ingrevia Limited | 0.87% | up 0.03 pts | ₹47.4 Cr | up ₹3.5 Cr | Added |
| Pfizer Limited | 0.78% | up 0.29 pts | ₹42.5 Cr | up ₹16.9 Cr | Added |
| Cash, TREPS & receivables | 0.69% | down 5.22 pts | ₹37.6 Cr | down ₹272 Cr | Trimmed |
| Healthcare Global Enterprises Limited | 0.48% | up 0.07 pts | ₹26 Cr | up ₹4.8 Cr | Added |
| Alkem Laboratories Limited | 0.47% | up 0.43 pts | ₹25.6 Cr | up ₹23.4 Cr | Added |
| Biocon Limited | 0.02% | up <0.01 pts | ₹1.1 Cr | up ₹5 L | Added |
What changed, May 2021 to Jun 2021
New New positions (2)
- Orchid Pharma Limited1.7% · ₹91.4 Cr
- Krishna Institute Of Medical Sciences Limited1.5% · ₹82.8 Cr
Exited Exited (0)
None.
Added Biggest additions
- Apollo Hospitals Enterprise Limitedup ₹94.6 Cr (+1.62% pts)
- Divi's Laboratories Limitedup ₹66.6 Cr (+0.90% pts)
- Torrent Pharmaceuticals Limitedup ₹50.8 Cr (+0.84% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since May 2021, the weight rose most in Healthcare Services (+3.0 pts), and fell most in Pharmaceuticals & Biotechnology (−2.7 pts) and Pharmaceuticals (−0.3 pts).
- Healthcare Services17.5% → 20.6%+3.0 pts
- Pharmaceuticals & Biotechnology79.0% → 76.3%−2.7 pts
- Pharmaceuticals2.6% → 2.3%−0.3 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Jun 2020 | Dec 2020 | Mar 2021 | May 2021 | Jun 2021 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 78.0% | 79.4% | 79.7% | 79.0% | 76.3% |
| Healthcare Services | 19.9% | 18.2% | 17.5% | 17.5% | 20.6% |
| Pharmaceuticals | 2.2% | 2.4% | 2.3% | 2.6% | 2.3% |
| Chemicals & Petrochemicals | — | — | 0.6% | 0.9% | 0.9% |
Allocation in Jun 2021change vs May 2021
- Pharmaceuticals & Biotechnology (16)76.3%▼ 2.7 pts
- Healthcare Services (6)20.6%▲ 3.0 pts
- Pharmaceuticals (1)2.3%▼ 0.3 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal.
Cash & debt, Jun 2021
0.7%
▼ 5.2 pts vs May 2021
- Cash alone
- 0.7%
- cash and net receivables
- A year earlier
- 1.9%
- Jun 2020 · now ▼ 1.2 pts
- Last 12 months
- 0.6% – 5.9%
- lowest to highest · record 5.9% in May 2021
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.